Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guangzhou Magigen Biotechnology is a specialized biotechnology company focused on the development and production of high-end enzymes and molecular diagnostic reagents. The company is a prominent provider of CRISPR-related proteins, including various Cas nucleases such as Cas9, Cas12, and Cas13, which are essential for gene editing and next-generation molecular diagnostics. Magigen's product portfolio extends to isothermal amplification reagents, NGS library preparation kits, and raw materials for in vitro diagnostics (IVD). By leveraging its expertise in protein engineering, the company supports researchers and industrial partners in fields ranging from clinical pathology to agricultural testing. Magigen is headquartered in Guangzhou's Science City and maintains a strong focus on innovation in rapid, point-of-care testing technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guangzhou Magigen Biotechnology.